Home › Research › Lewy body dementia
Dementia and PDE5 inhibitors: A retrospective cohort study of veterans
Singh V, Sharma R, Sharma M, Wiegmann T, Sharma R.. Research Square, 2026-10-13
Topic: Drug trials: efficacy and safety
Plain-language summary
Background Dementia is an escalating global public health crisis with profound consequences. Repurposing established medications, such as phosphodiesterase type 5 (PDE5) inhibitors, offers a promising avenue for mitigating dementia risk and progression. Methods This retrospective cohort study utilized national data from the U.S. Department of Veterans Affairs to examine whether PDE5 inhibitor use was associated with reduced dementia incidence and delayed dementia diagnosis among 878,240 male Veterans with erectile dysfunction (ED). Propensity score matching generated well-balanced exposed (PDE5 inhibitor users) and unexposed control groups. Baseline dementia prevalence was similarly low in both groups. Results During longitudinal follow-up, new diagnoses of Alzheimer, frontotemporal, and vascular dementia were significantly lower among PDE5 inhibitor users than among controls, with odds ratios (ORs) of 0.91 for Alzheimer dementia (95% CI, 0.85–0.96), 0.83 for frontotemporal (95% CI, 0.69–1.00), and 0.84 for vascular dementia (95%, CI 0.79–0.89). Time-to-diagnosis analyses and Kaplan–Meier curves further demonstrated that PDE5 inhibitor exposure was associated with substantial delays in dementia onset, ranging from two to three years across several subtypes. Associations persisted across sensitivity analyses. Conclusions The observed protective effect may be explained by vascular and neuroprotective mechanisms unique to PDE5 inhibitors. Limitations include reliance on administrative codes, lack of adherence data, and restriction to a male Veteran population with ED, which may limit generalizability. Nonetheless, these findings highlight the potential of PDE5 inhibitors to reduce dementia incidence and delay its onset, warranting further prospective research and possible clinical trials to explore this novel therapeutic strategy.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Singh, V., Sharma, R., Sharma, M., & Wiegmann, T. (2026). Dementia and PDE5 inhibitors: A retrospective cohort study of veterans. Research Square. https://doi.org/10.21203/rs.3.rs-11010754/v1
Vancouver
Singh V, Sharma R, Sharma M, Wiegmann T. Dementia and PDE5 inhibitors: A retrospective cohort study of veterans. Research Square. 2026. doi:10.21203/rs.3.rs-11010754/v1.
BibTeX
@article{singh2026-628d86a7,
author = {Singh, V. and Sharma, R. and Sharma, M. and Wiegmann, T.},
title = {{Dementia and PDE5 inhibitors: A retrospective cohort study of veterans}},
journal = {Research Square},
year = {2026},
doi = {10.21203/rs.3.rs-11010754/v1},
url = {https://doi.org/10.21203/rs.3.rs-11010754/v1}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Department of Veterans Affairs to examine whether PDE5 inhibitor use was associated with reduced dementia incidence and delayed dementia diagnosis among 878,240 male Veterans with erectile dysfunction (ED).
- Results During longitudinal follow-up, new diagnoses of Alzheimer, frontotemporal, and vascular dementia were significantly lower among PDE5 inhibitor users than among controls, with odds ratios (ORs) of 0.91 for Alzheimer dementia (95% CI, 0.85–0.96), 0.83 for frontotemporal (95% CI, 0.69–1.00), and 0.84 for vascular dementia (95%, CI 0.79–0.89).
- Time-to-diagnosis analyses and Kaplan–Meier curves further demonstrated that PDE5 inhibitor exposure was associated with substantial delays in dementia onset, ranging from two to three years across several subtypes.
- Nonetheless, these findings highlight the potential of PDE5 inhibitors to reduce dementia incidence and delay its onset, warranting further prospective research and possible clinical trials to explore this novel therapeutic strategy.
Study details
- Study designcohort study
- Evidence strengthModerate
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 35 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 22 of the 62 points we could judge it on, which is 35 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (Research Square) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 22 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 22 of the 62 points we could judge it on is 35 out of 100. |
| Total | 35 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Lewy body dementia from nearby years
Also tagged “cholinesterase”
272 studies in the library carry the topic tag “cholinesterase”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 272 tagged studies.